What is Ocular Therapeutix's EV / sales?

Ocular Therapeutix (OCUL) reported EV / sales of 24.1× in Q1 2026.

How has Ocular Therapeutix's EV / sales changed year-over-year?

Ocular Therapeutix's EV / sales increased by 61.4% year-over-year, from 15× to 24.1×.

What is the long-term trend for Ocular Therapeutix's EV / sales?

Over 5 years (2020 to 2025), Ocular Therapeutix's EV / sales has grown at a -14.1% compound annual growth rate (CAGR), from 79.5× to 37.1×.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

Ocular Therapeutix OCUL EV / sales

EV / sales at other companies

Regeneron PharmaceuticalsREGN

5.5×+0.6×

Bausch + LombBLCO

2×0.0×

Tarsus Pharmaceuticals, Inc.TARS

5.6×-3.1×

Ultragenyx PharmaceuticalRARE

2.7×-4.0×

PBH

Prestige Consumer HealthcarePBH

3.5×-1.1×

Arcutis Biotherapeutics, Inc.ARQT

7.2×-1.8×

Other financials

Income statement

See full

Revenue$10.8M+0.8%

Gross profit$9.5M+0.2%

Operating income-$93.3M-46.0%

Net income-$88.6M-38.3%

EPS (diluted)-$0.40-5.3%

Balance sheet

See full

Cash & equivalents$666.7M+90.7%

Total debt$79.5M+4.2%

Total equity$581.6M+119%

Total assets$732.5M+80.5%

Cash flow

See full

Operating cash flow-$66.0M-47.7%

CapEx$4.7M+141%

Free cash flow-$70.7M-51.6%

Valuation

See full

Market cap$2.21B+58.2%

Enterprise value$1.63B+40.8%

P/S42.6×+19.1×

Profitability

See full

Gross margin87.2%-3.4pp

Operating margin-575.4%+1,233pp

Net margin-558.2%+1,493pp

FCF margin-463%+2,860pp

Returns & leverage

See full

Return on equity-68.6%+17.0pp

Debt / equity0.1×-0.2×

Current ratio14.8×+4.6×

Where this comes from

Calculated from Ocular Therapeutix’s reported figures.

enterprise value/total revenue=24.1×

Based on the most recent quarter.

The official record: Ocular Therapeutix’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ocular Therapeutix's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Ocular Therapeutix's EV / sales?: Ocular Therapeutix (OCUL) reported EV / sales of 24.1× in Q1 2026.
How has Ocular Therapeutix's EV / sales changed year-over-year?: Ocular Therapeutix's EV / sales increased by 61.4% year-over-year, from 15× to 24.1×.
What is the long-term trend for Ocular Therapeutix's EV / sales?: Over 5 years (2020 to 2025), Ocular Therapeutix's EV / sales has grown at a -14.1% compound annual growth rate (CAGR), from 79.5× to 37.1×.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.